[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA51565A - Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble - Google Patents

Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Info

Publication number
MA51565A
MA51565A MA051565A MA51565A MA51565A MA 51565 A MA51565 A MA 51565A MA 051565 A MA051565 A MA 051565A MA 51565 A MA51565 A MA 51565A MA 51565 A MA51565 A MA 51565A
Authority
MA
Morocco
Prior art keywords
intermediaries
preparation
guanylate cyclase
new processes
soluble guanylate
Prior art date
Application number
MA051565A
Other languages
English (en)
Inventor
Ahmad Hashash
Vishnu Vardhan Reddy Karnati
William Kissel
Takashi Nakai
Wayne C Schairer
Debra Jane Wallace
Yuguang Wang
Song Xue
Fenger Zhou
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/fr
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MA51565A publication Critical patent/MA51565A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA051565A 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble MA51565A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-02-22 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
MA51565A true MA51565A (fr) 2020-11-18

Family

ID=65279655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051565A MA51565A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Country Status (17)

Country Link
US (3) US11274096B2 (fr)
EP (2) EP3737679B1 (fr)
JP (2) JP7357621B2 (fr)
KR (1) KR20200106920A (fr)
CN (3) CN118184645A (fr)
AU (2) AU2019206560B2 (fr)
BR (1) BR112020013985A2 (fr)
CA (1) CA3087943A1 (fr)
CL (3) CL2020001814A1 (fr)
ES (1) ES2963447T3 (fr)
IL (2) IL275748B1 (fr)
JO (1) JOP20200165A1 (fr)
MA (1) MA51565A (fr)
MX (3) MX2020007364A (fr)
SG (1) SG11202006311SA (fr)
TW (2) TW202402741A (fr)
WO (1) WO2019140095A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102487872B1 (ko) * 2016-07-07 2023-01-12 사이클리온 테라퓨틱스, 인크. 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법
CN118184645A (zh) 2018-01-10 2024-06-14 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
CN118221650A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
CN118221649A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588465B1 (fr) * 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
CN108912111B (zh) * 2013-03-15 2021-09-14 赛克里翁治疗有限公司 化合物及药用组合物
EP3094327A1 (fr) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
WO2016044441A1 (fr) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
CN107406422B (zh) * 2014-09-17 2022-02-01 赛科理音医疗有限公司 作为sGC刺激剂的吡唑衍生物
JP6952707B2 (ja) 2015-11-30 2021-10-20 サイクレリオン・セラピューティクス,インコーポレーテッド sGC刺激薬を含んでなる固体分散剤
KR102487872B1 (ko) 2016-07-07 2023-01-12 사이클리온 테라퓨틱스, 인크. 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법
US11834444B2 (en) 2016-07-07 2023-12-05 Cyclerion Therapeutics, Inc. Processes for preparation of soluble guanylate cyclase stimulators
CN118184645A (zh) 2018-01-10 2024-06-14 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物

Also Published As

Publication number Publication date
CA3087943A1 (fr) 2019-07-18
EP3737679A1 (fr) 2020-11-18
MX2023000045A (es) 2023-02-01
JOP20200165A1 (ar) 2022-10-30
CN118221665A (zh) 2024-06-21
ES2963447T3 (es) 2024-03-27
MX2023000044A (es) 2023-02-01
US12030874B2 (en) 2024-07-09
TW201932450A (zh) 2019-08-16
AU2019206560B2 (en) 2023-08-24
CN111902410B (zh) 2024-04-19
EP4249469A2 (fr) 2023-09-27
EP4249469A3 (fr) 2023-12-27
CN111902410A (zh) 2020-11-06
US20210053962A1 (en) 2021-02-25
IL314714A (en) 2024-10-01
CN118184645A (zh) 2024-06-14
AU2023270260A1 (en) 2023-12-07
EP3737679B1 (fr) 2023-09-06
JP2023182647A (ja) 2023-12-26
CL2022000907A1 (es) 2022-10-21
WO2019140095A8 (fr) 2020-06-18
US20230339928A1 (en) 2023-10-26
US11274096B2 (en) 2022-03-15
US11708361B2 (en) 2023-07-25
WO2019140095A1 (fr) 2019-07-18
CL2020001814A1 (es) 2020-11-06
TW202402741A (zh) 2024-01-16
JP2021511299A (ja) 2021-05-06
CL2022000904A1 (es) 2022-10-21
IL275748A (en) 2020-08-31
US20220024909A1 (en) 2022-01-27
EP3737679C0 (fr) 2023-09-06
JP7357621B2 (ja) 2023-10-06
IL275748B1 (en) 2024-09-01
BR112020013985A2 (pt) 2020-12-01
MX2020007364A (es) 2020-11-18
SG11202006311SA (en) 2020-07-29
KR20200106920A (ko) 2020-09-15
AU2019206560A1 (en) 2020-07-30
TWI821237B (zh) 2023-11-11

Similar Documents

Publication Publication Date Title
MA46479A (fr) Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
MA51565A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA52308A (fr) Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MA45154A (fr) Procédés de préparation d'oligomères
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
IL264001A (en) A facility for extracorporeal oxidation using a membrane and simultaneous renal replacement therapy
MA46641A (fr) Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
MA52796A (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
MA49705A (fr) Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA45603A (fr) Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble